Researchers plan to study resveratrol's ability to curb diabetes risk

A team of researchers from the Albert Einstein College of Medicine at Yeshiva University was recently granted $600,000 by the American Diabetes Association to study the effects of the antioxidant resveratrol on individuals with insulin resistance, a condition that often develops into type 2 diabetes.

Resveratrol is a chemical compound that is most commonly found in red grapes. In recent years it has been touted for its potential to mitigate heart risk. Additionally, recent investigations have shown that it may also influence insulin tolerance. A potential natural compound that mitigates diabetes risk could be a major advancement for those with pre-diabetes. A high percentage of these individuals will go on to develop the condition.

This is why the researchers were so interested in studying resveratrol further. The news source reports that the team is planning to use the grant to fund a six-week trial. A group of 30 participants will either be given an active supplement or placebo to take following meals. The study will examine the effect that this has on glucose metabolism.

"Given the easy availability, low cost and apparent safety of resveratrol supplementation, a positive finding could have an enormous impact on human health," said Jill Crandall, who will lead the investigation.

Earlier studies have shown that resveratrol may be a powerful nutrient in the battle against insulin resistance and diabetes. A recent investigation from Boston University researchers showed that human adipose tissue treated with resveratrol becomes less inflamed. In the human body, inflamed tissue is more likely to become resistant to insulin, increasing the risk of type 2 diabetes.

The Yeshiva University researchers believe that if their findings back up these earlier investigations, it could lead to the development of new medications that may curb an individual's chances of developing type 2 diabetes.
Last updated on

Don't Miss Out! Get the FREE EndocrineWeb eNewsletter!

Sign up to receive treatment and research updates, news, and helpful tips on managing your condition.
close X